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Abstract 
Background  Atrial fibrillation (AF) is the most frequent arrhythmia, and its prevalence is increasing with aging. We aimed to com-
pare the long-term outcome data of patients < 65 years vs.  65 years who underwent catheter ablation (CA) for drug-refractory AF. Methods  
Consecutive patients with primary pulmonary vein isolation performed between March 2001 and December 2011, and those who completed 
a five-year of follow-up were divided into two groups: patients aged < 65 years into group 1, and patients aged  65 into group 2. Long-term 
outcome data concerning mortality, thromboembolic events (TE) and success rates were compared between these groups. Results  A total 
number of 390 patients were included, group 1 contained 310 patients, and 80 patients in group 2. In group 2, patients had more often impaired 
renal function (P < 0.001) and thyroid disease (P = 0.047). A total of fifteen patients died during the 6.63 ± 2.1 years of follow-up, with a sig-
nificantly higher incidence in the older group (8/80 vs. 7/310 patients, P = 0.004). The majority of fatal outcome was due to cancerous dis-
eases in both groups. No difference was observed concerning the long-term TE rate (12/310 vs. 4/80 patients, P = 0.75). Rhythm control 
failed in 25.9% of the patients, with no difference between the groups: 26.4% in group 1 vs. 23.7% in group 2 (P = 0.67). Conclusions  
Despite growing prevalence of AF in aging population, the elderly patients are underrepresented in CA procedures. Similar clinical success 
and TE complication rate are observed between the age-groups. Our data suggest more liberal criteria might be applied while selecting pa-
tients for AF ablation. 
J Geriatr Cardiol 2017; 14: 569574. doi:10.11909/j.issn.1671-5411.2017.09.004 
Keywords: Atrial fibrillation; Catheter ablation; Clinical outcome; The elderly; Thromboembolic complication 
 
 
1  Introduction 
Atrial fibrillation (AF) is the most frequent arrhythmia, 
and its prevalence is progressively increasing with the 
growing population of elderly patients.[1,2] AF prevalence is 
estimated to double in the next 50 years.[3] Due to the aging 
of the population and the increasing prevalence of AF as 
well as its associated comorbidities, AF has become an im-
portant public health issue.[1,2] Pulmonary vein isolation 
(PVI) by catheter ablation (CA), is an established therapeu-
tic option of drug-resistant AF in younger patients and im-
plemented in guidelines. However, the optimal AF man-
agement in elderly AF patients is still unclear, as elderly 
adults are generally underrepresented in randomized clinical  
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trials.[4,5] The survey conducted by the European Heart Rhy-
thm Association, investigating the clinical practise in ar-
rhythmia management Europe-wide, detected only 18.4% of 
the enrolled centres performed AF ablation without age 
limitation.[2,6] The main reason for rejection of AF ablation 
in more than 10% of patients ≥ 75 years were concerns re-
garding procedure-related complications.[2,6] To date, only 
few studies have evaluated safety and efficacy outcomes of 
elderly patients who underwent CA of AF and their results 
are contradictory.[6–11] The present study sought to compare 
the long-term clinical outcome of CA of AF between pa-
tients aged < 65 years vs. ≥ 65 years.  
2  Methods 
Consecutive patients with drug-refractory AF who un-
derwent PVI as the index procedure between March 2001 
and December 2011, and who completed the five-year of 
follow-up (FU) were enrolled into the present study. Data 
collection for this study from our prospective registry was 
approved by the institutional review committee and was 
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carried out in accordance with the ethical principles for 
medical research involving human subjects founded by Hel-
sinki’s declaration. All patients were eligible for AF abla-
tion based on the currently accepted ACC/AHA/ESC guide-
lines.[12,13] All patients provided informed consent prior the 
CA procedures. Patients were divided into two groups based 
on their age at the index procedure. Patients aged < 65 years 
were included into group 1. The second group of the patients 
were aged ≥ 65 years, and will be referred to in the text as 
those in group 2. Long-term outcome data was retrospectively 
analysed and compared between these groups. Exclusion cri-
teria were a prior PVI, severe valvular heart disease, inability 
to provide informed consent, contraindication to the use of 
anticoagulation post-ablation, presence of intracavital thrombi 
detected by pre-procedural transoesophageal echocardiogra-
phy and/or computed tomography. Altogether, 390 patients 
were selected for the final analysis. 
2.1  Study variables  
Baseline characteristics and clinical data were retrieved 
from the “Elpado” system, which is a computerized, institu-
tional electronic patient dossier system. The advantage of 
this system is that it contains all patient-related health issues, 
also provided by peripheral health institutes in a scanned letter 
form. Thus, all relevant health events investigated in the pre-
sent study including stroke, TIA and mortality which were 
recorded not only at the Cardiology Department of Erasmus 
MC but also at different Subscpecility’s Department, could be 
tracked with high probability as well. The following data 
were compared between the investigated groups: age, gen-
der, AF type, AF duration. 
Cardiovascular comorbid diseases were retrieved as dia-
betes mellitus (DM), hyperlipidemia (HLP), hypertension 
(HT). Furthermore, the function of the renal and thyroid 
system was investigated. The following echocardiographic 
parameters were compared: left atrial (LA) size, ejection 
fraction (EF) and mitral insufficiency (MI). The stroke risk 
stratification (CHA2DS2-VASC) score was calculated from 
the individual stroke risk factors: congestive heart failure, 
hypertension, age ≥ 75 years, diabetes mellitus, stroke or 
TIA, vascular disease, sex category (female) and age 65–74.9 
years. 
2.2  CA and peri-procedural management of antico-
agulation 
Complete electrical isolation of all pulmonary veins con-
trolled by multipolar circular catheter was the procedural 
endpoint in all patients. Wide variety of techniques includ-
ing cryoballoon (CB) in 66.6% and radiofrequency (RF) 
ablation in 33.3% of the entire patient cohort was performed. 
Single PVI was performed in 51.5% (67/130) of the RF 
ablated patients. Additional linear lines were placed in 
34.6% (45/130) of the RF ablations, while PVI+cavotricus-
pidal isthmus (CTI) ablation was performed in 15.3% 
(18/130).  
The peri-ablation approach of anticoagulation and anti-
arrhythmic drug management as well as the follow-up me-
thodology was determined by the patient’s electrophysiolo-
gist based on the currently accepted guidelines. Unsuccess-
ful ablation was defined as rhythm control failure even de-
spite repeated CA procedure and/or being on rhythm-control 
anti-arrhythmic drug (AAD) therapy. These patients were 
maintained on rate control AAD management with or without 
pacemaker (PM) backup. Otherwise, a MAZE procedure or a 
His-bundle ablation following PM implantation was accom-
plished.  
2.3  Follow-up 
The follow-up period started in all participants at the date 
of the PVI procedure and continued until outcome event 
(stoke/TIA after PVI), death, loss to follow-up or December 
31, 2016, whichever came first. 
2.4  Statistical analysis 
Continuous variables are expressed as mean ± SD or me-
dian and quartiles (Q1–Q3). Categorical data are shown as 
percentages. For statistical comparison, the not-normally dis-
tributed variables were compared with the Man-Whitney test, 
while ordinal variables were analyzed with the Chi-square test 
and nominal variables with the Student t-test. Statistical 
analysis was performed with SPSS Statistics for Windows, 
Version 24.0. 
3  Results  
Altogether, 390 patients were included into the final analy-
sis, which 310 and were enrolled into group 1 and 80 were 
selected into group 2. 
3.1  Patient characteristics 
The baseline demographic and clinical data of the patients 
are summarized in Table 1. In the elderly cohort, more female 
patients were present (P = 0.023). Patients in group 2 also 
suffered more often from impaired renal function (P < 0.001) 
and from thyroid disease (P = 0.047). There was no signifi-
cant difference between the study groups regarding comorbid 
conditions such as hypertension, diabetes, hyperlipidaemia, 
and hearth failure. Similarity was observed among the groups 
concerning smoking habits, and body mass index (Table 1). 
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Table 1.  Patient demographic and echocardiographic data. 
 General patient cohort Patients aged < 65 yrs Patients aged ≥ 65 yrs P-value 
Female sex 105/390 (26.92%) 75/310 (24.19%) 30/80 (37.50%) 0.023 
Paroxysmal AF 352/390 (90.25%) 280/310 (90.32%) 72/80 (90.0%) 0.833 
AF duration 3.60 ± 5.03 3.64 ± 5.30 3.73 ± 3.85 0.869 
LA size, mm 43.16 ± 6.52 43.22 ± 6.63 42.91 ± 6.25 0.719 
Ejection fraction, % 61.19 ± 14.26 61.21 ± 14.28 61.08 ± 14.32 0.955 
Mitral insufficiency 45/390 (11.53%) 35/310 (11.29%) 10/80 (12.50%) 0.699 
Congestive heart failure 19/390 (4.87%) 13/310 (4.19%) 6/80 (7.50%) 0.243 
Hypertension 180/390 (46.15%) 135/310 (43.54%) 45/80 (56.25%) 0.059 
Diabetes 73/390 (18.71%) 17/310 (5.48%) 8/80 (10.0%) 0.197 
Hyperlipidemia 25/390 (6.41%) 52/310 (16.77%) 21/80 (26.25%) 0.076 
COPD 9/390 (2.30%) 8/310 (2.58%) 1/80 (1.25%) 0.693 
Thyroid dysfunction 35/390 (8.97%) 23/310 (7.41%) 12/80 (15.0%) 0.047 
Pulmonary embolism 2/390 (0.51%) 2/310 (0.64%) 0/80 (0%) 1.000 
Stroke/TIA before PVI 22/390 (5.64%) 14/310 (4.51%) 8/80 (10.0%) 0.097 
Vascular disease 15/390 (3.84%) 10/310 (3.22%) 5/80 (6.25%) 0.203 
Smoking 35/390 (8.97%) 31/310 (10.0%) 4/80 (5.0%) 0.192 
Body mass index 27.79 ± 10.29 28.66 ± 11.74 25.31 ± 3.20 0.123 
GFR 79.45 ± 16.52 81.95 ± 15.66 69.96 ± 16.40 < 0.001 
CHA2DS2VASC score 1.24 ± 1.14 0.94 ± 0.93 2.41 ± 1.15 < 0.001 
CHA2DS2VASC score 0 117/390 (30.0%) 114/310 (36.77%) 3/80 (3.75%) < 0.001 
CHA2DS2VASC score 1 141/390 (36.15%) 128/310 (41.29%) 13/80 (16.30%) < 0.001 
CHA2DS2VASC score 2 81/390 (20.76%) 50/310 (16.12%) 31/80 (38.75%) < 0.001 
CHA2DS2VASC score 3 33/390 (8.46%) 14/310 (4.51%) 19/80 (23.75%) < 0.001 
CHA2DS2VASC score 4 13/390 (3.33%) 2/310 (0.64%) 11/80 (13.75%) < 0.001 
CHA2DS2VASC score 5 4/390 (1.0%) 2/310 (6.45%) 2/80 (2.50%) 0.188 
CHA2DS2VASC score 6 1/390 (0.25%) 0/310 (0%) 1/80 (1.25%) 0.205 
Data are presented as mean ± SD or n (%). AF: atrial fibrillation; CHA2DS2VASC: stroke stratification score; COPD: chronic obstructive pulmonary disease; 
GFR: glomerular filtration rate; LA: left atrial appendage; PVI: pulmonary vein isolation; TIA: transient ischemic attack. 
 
No significant difference could be identified between the 
investigated groups concerning the echocardiographic pa-
rameters such as EF, LA size, and mitral valve insufficiency 
(Table 1). While, no difference was observed between the groups 
studying the thromboembolic history, the CHA2DS2VASC 
score profile was significantly higher in group 2 (P < 
0.001). 
3.2  Procedural data 
The procedural data are summarized in Table 2. Of the 
entire patient population, 66% (260/390) underwent cryo-
balloon ablation as an index procedure, while 33% (130/310) 
received radiofrequency CA. There was no difference re-
garding the energy source of ablation (RF and CB) between 
the age-groups (Table 2). Cryoballoon ablation was utilized 
in 68% (211/310) in the group 1, whilst in 61% (49/80) in 
group 2. Radiofrequency energy was applied in 32% 
(99/310) among patients aged less than 65 years and in 39% 
(30/80) in group 2. There was no significant difference in 
the radiation and procedure time between the examined 
groups (Table 2). Redo ablation was executed in 47% 
(184/390) within the entire patient population, significantly 
more often performed in the group 1 (156/310, 50.3%) as 
compared to group 2 (28/80, 35%) (P = 0.017).  
Furthermore, His-bundle ablation was done in 4.8% 
(15/310) in the group 1 similarly to 8.7% (7/80) in the group 
2. In addition, 22 out of 310 (7%) in group 1, likewise 7 out 
of 80 patients (8.7%) in group 2 underwent a MAZE pro-
cedure after PVI. There was no significant difference in PM 
implantation performed prior to or after the PVI procedure 
between the studied groups.  
3.3  Mortality, thromboembolic events   
The long-term clinical outcome data are shown in Table 3. 
Altogether 15 patients died during the mean 6.63 ± 2.1 years 
of FU. In group 2, a total of 8 out of 80 (10.0%) patients 
died, which is a significantly higher incidence compared to 
7 out of 310 deaths (2.3%) in group 1 (P = 0.004). The 
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Table 2.  Procedural data. 
 General patient cohort Patients aged < 65 yrs Patients age ≥ 65 yrs P-value 
Cryoballoon ablation 260/390 (66.6%) 212/310 (68.38%) 48/80 (60.0%) 0.183 
Radiofrequency ablation 130/390 (33.33%) 98/310 (31.61%) 32/80 (40.0%) 0.183 
Redo ablation 184/390 (47.2%) 156/310 (50.32%) 28/80 (35.0%) 0.017 
Number of redo ablations per patient 0.58 ± 0.69 0.71 ± 0.4 0.58 ± 0.65 0.004 
Radiation time, min 52.65 ± 28.1 53.64 ± 26.62 48.86 ± 25.86 0.161 
Procedure time, min 217.50 ± 86.2 218.17 ± 86.13 214.77 ± 87.14 0.768 
MAZE procedure after PVI 29/390 (7.43%) 22/310 (7.09%) 7/80 (8.75%) 0.634 
His-ablation after PVI 22/390 (5.64%) 15/310 (4.83%) 7/80 (8.75%) 0.179 
PM implantation before PVI 14/390 (3.58%) 10/310 (3.22%) 4/80 (5.0%) 0.498 
PM/CRT implantation after PVI 29/390 (7.43%) 31/310 (10.0%) 8/80 (10.0%) 1.000 
Failed rhythm control strategy 101/390 (25.89%) 82/310 (26.45%) 19/80 (23.75%) 0.670 
Data are presented as mean ± SD or n (%). CRT: cardiac resynchronization therapy; PM: pacemaker; PVI: pulmonary vein isolation. 
Table 3.  Outcome data after PVI for AF. 
 General patient cohort Patients aged < 65 yrs Patients aged  65 yrs P-value 
Mortality 15/390 (3.84%) 7/310 (2.25%) 8/80 (10.0%) 0.004 
Stroke/TIA occurrence 16/390 (4.10%) 12/310 (3.87%) 4/80 (5.00%) 0.750 
Stroke-alone occurrence 6/390 (1.53%) 4/310 (1.29%) 2/80 (2.5%) 0.607 
TIA-alone 10/390 (2.56%) 8/310 (2.58%) 2/80 (2.50%) 1 
Stroke/TIA occurrence after PVI, yrs 4.71 ± 3.11 5.17 ± 3.38 3.30 ± 1.79 0.186 
Stroke occurrence after PVI, yrs 5.83 ± 3.10 7.33 ± 2.29 2.84 ± 2.33 0.008 
TIA occurrence after PVI, yrs 4.03 ± 3.08 4.10 ± 3.42 3.75 ± 1.84 0.859 
Follow-up period, yrs 6.63 ± 2.10 6.78 ± 2.15 6.05 ± 1.80 0.002 
Data are presented as mean ± SD or n (%). AF: atrial fibrillation; PVI: pulmonary vein isolation; TIA: transient ischemic attack. 
 
cause of death in all but two patients was cancerous disease. 
One patient died from intracranial bleeding and in the other 
patient the fatal outcome was caused by ischemic stroke. 
Both patients were aged above 65 years. Neither the 
long-term stroke/TIA occurrence [4/80 patients (5%) in 
group 2 vs. 12/310 (3.9%) patients in group 1] nor the 
stroke-alone [2/80 (2.5%) in group 2 vs. 4/310 (1.3%) pa-
tients in group 1], and the TIA-alone [2/80 (2.5%) in group 
2 vs. 8/310 (2.5%) patients in group 1] occurrence differed 
significantly between the age-groups. However, stroke-alone 
in group 1 occurred significantly later following the PVI 
with a mean of 7.33 ± 2.29 years as compared to a 2.84 ± 
2.33 years in the older age group (P = 0.008). 
3.4  Clinical outcome 
Unsuccessful ablation was observed altogether in 25.9% 
of the patient cohort, with no statistically significant differ-
ence among the groups: 82/310 (26.4%) patients in group 1 
vs. 19/80 (23.7%) patients in group 2 (P = 0.67). In the pre-
sent mixed AF cohort, 289 out of 390 (74.1%) patients 
could be maintained in SR with or without AAD-therapy. In 
total, a mean of 0.58 ± 0.69 redo procedures was performed. 
No difference in long-term clinical success was found be-
tween the two age groups as 228/310 (73.5%) patients in the 
younger age group with a mean of 0.71 ± 0.4 procedures 
remained in SR, while in 61/80 (76.2%) patients in the eld-
erly group after a mean of 0.58 ± 0.65 procedures SR could 
be retained (Table 3). 
4  Discussion  
The major finding of the present study is that the 
long-term clinical success and thromboembolic complica-
tion rate after PVI do not differ between patients aged < 65 
years as compared to elderly patients aged ≥ 65 years. 
Moreover, similar clinical success rate can be achieved be-
tween the age-groups, despite the fact that more redo pro-
cedures per patient were performed in the group with 
younger patients. Interestingly enough, stroke-alone oc-
curred significantly later among younger patients as com-
pared to those aged above 65 years. Our data suggest that, 
more liberal selection criteria for CA of AF should be con-
sidered, irrespective of the age of the patients. This would 
be especially important given the fact that, despite the in-
creasing prevalence of AF among the elderly patients, they 
are generally underrepresented in AF ablation procedures.  
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4.1  Long-term mortality 
The study by Srivasta, et al.,[14] investigating 6207 pa-
tients undergoing AF ablation, showed that age ≥ 80 years 
was an independent predictor factor leading to more than 
8-fold increase in probability of 30-day death after PVI. 
Hoffman, et al.,[15] demonstrated with the German ablation 
registry, that age was an independent predictor of death and 
severe, nonfatal peri-procedural complications. On the con-
trary, Moser, et al.,[2] reported that the in-hospital death rate 
was not higher in the elderly cohort aged ≥ 75 years as com-
pared to younger patients after CA of AF. At a first glance, 
our long-term analysis appears to show a higher mortality 
rate among the elderly patients after PVI. However, the AF 
ablation related mortality was not excessively high in the 
elderly groups. Furthermore, it is essential to emphasize that 
the majority of the fatal outcomes were caused by cancerous 
disease.   
4.2  Long-term thromboembolic complications 
The world-wide survey of CA of AF by Cappato, et 
al.,[13] revealed that major complications occurred in 4.5% 
after PVI in patients aged between 15 and 90 years. The 
study by Corrado, et al.,[9] Bertaglia, et al.,[16] Bunch, et 
al.,[17] and Zado, et al.,[7] demonstrated that there is no in-
creased risk of adverse event among elderly patients after 
PVI. Furthermore, studies by Bunch, et al.,[17] Santangeli, et 
al.,[8] and Metzner, et al.,[11] analyzing patients aged ≥ 75 
years found that stroke rates ranged from 0 to 0.7% and TIA 
rates from 0 to 0.3%. Moser, et al.,[2] found a 0.2% 
peri-procedural complication rate which is in line with the 
previous results, however there was a significant difference 
among age-groups with a 1.3% peri-procedural stroke rate 
in patients ≥ 75 years vs. 0.1% in younger patients (P = 
0.001). In contrast, Oral, el al.,[18] could find an increase in 
TE events in patients aged above 70 years after PVI. Also, 
Guiot, et al.,[19] could show that age > 75 years is an inde-
pendent predictor of late cerebrovascular event after AF 
ablation. Our results confirm that long-term TE event does 
not differ significantly between younger patients aged < 65 
years as compared to elderly ones aged ≥ 65 years (P = 
0.75). However, our overall TE event rate is higher than 
reported in previous studies, as all the stroke/TIA occur-
rence was observed in 16 out of 390 (4.1%) patients, with 
4/310 (3.87%) patients in the younger age group and with 
4/80 (5%) patients in the elderly age group. This extensional 
result might be explained by the used FU methodological 
specialties. The “Elpado” electronic patient dossier dataset 
including all patient-related health issues, also those pro-
vided by peripheral health centers, made possible to gather 
all relevant outcome data. Our present study had an ex-
tended FU as compared to the studies mentioned above, 
with a mean FU duration of 6.63 ± 2.1 years. In our opinion, 
this is the essential minimal duration of a FU period needed 
to recognize TE events after PVI, as all stroke/TIA events 
happened with a mean of 5.17 ± 3.38 years in the younger 
and with a mean of 3.30 ± 1.79 years in the older patient 
cohort. Furthermore, it is important that the stroke-alone 
event occurred significant later after PVI with a mean of 
7.33 ± 2.29 in the younger age group as compared to 2.84 ± 
2.33 year in the elderly age group (P = 0.008). One could 
argue that because of the length of these intervals, that these 
TE complications are not primary being caused by the abla-
tion procedure itself, but could for example being caused by 
diminished atrial transport function. Based on these findings, 
better anticoagulation management and clearer guidelines 
on long-term FU methodologies following PVI procedures 
are required.  
4.3  Long-term clinical success 
Catheter ablation for AF was associated with a compara-
ble long-term clinical outcome among both investigated 
groups, despite the fact that more redo procedures in the 
younger age-group were performed. In the present mixed 
AF cohort, SR could be maintained in 74.1% of the patients 
with a mean of 0.58 ± 0.69 redo procedures. No difference 
in long-term clinical success was found between the 
age-groups, as in 73.5% of the younger patients and in 
76.2% of the elderly patients, SR could be preserved. Our 
findings are in line with the results of Metzner, et al.,[11] 
who demonstrated a 76% clinical success rate after a mean 
of 1.5 procedures of CA of paroxysmal AF in pts older than 
75 years. Our results are also comparable with the findings 
published by Santageli, et al.,[8] who found a 87% success 
rate of AF ablation in a mixed AF cohort aged > 80 years 
with a mean FU of 18 ± 6 months. Our data confirms that 
AF ablation in the elderly patients can provide a favorable 
long-term clinical outcome. Moreover, better understanding 
of AF mechanism evolving technological developments are 
essential to further improve the long-term AF ablation out-
comes.[20] 
4.4  Study limitations  
The present study is a retrospective, single-center study, 
investigating a relatively small patient cohort of patients 
who underwent CA for AF. Besides, a wide variety of en-
ergy sources for PVI and ablation strategies were used. Only 
a limited number of patients with persistent or long-strand-
ing persistent AF were analyzed. This study aimed to inves-
tigate as much elderly patients as possible, but still only few 
patients of the cohort were aged above 75 years.  
574 Kis Z, et al. Outcome of AF ablation in young and elderly patients 
 
Journal of Geriatric Cardiology | jgc@jgc301.com; http://www.jgc301.com 
4.5  Conclusions 
Catheter ablation for atrial fibrillation in patients ≥ 65 
years has a similar safety profile as compared to a younger 
patient cohort. No significant difference in thromboembolic 
complications following PVI is observed between the 
age-groups. Older patients have a comparable long-term 
clinical success rate compared to younger ones, despite less 
redo procedures were performed among the elderly patient 
population. Our data suggests, that more liberal selection 
criteria for drug-refractory AF ablation could be introduced, 
irrespective of the age of patients. Prospective, randomized, 
control trials with long-term follow-up are necessary to con-
firm our results. 
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